Le Lézard
Classified in: Covid-19 virus
Subject: Economic News/Analysis

Best's Commentary: Australia Business Interruption Test Case Raises More Questions than Answers for Insurers


Following the outcome of an Australian legal test case that considered the application of certain infectious disease exclusions in business interruption policies going against the insurance industry, some insurers are looking to reinforce their claims provisions and execute capital raising actions to bolster their solvency positions, according to a new AM Best commentary.

The judgment handed down by the New South Wales Court of Appeal brings into sharp focus the potential downside risk for the industry. With a unanimous ruling against the arguments made by the insurers on this test case, AM Best expects the question of pandemic business interruption coverage to remain a significant source of uncertainty for Australian commercial insurers.

In its Best's Commentary, "Australia Business Interruption Test Case Raises More Questions than Answers for Insurers," AM Best states that the re-evaluation and refinement of loss provisions for potential COVID-19-related business interruption exposures are expected to lead to an adverse impact on commercial insurers' operating earnings. The extent to which this affects capital positions remains to be seen, although AM Best views companies with strong financial flexibility and a track record of accessing capital markets as being best-placed to contend with adverse capital implications. Some smaller insurers exhibit limited financial flexibility due to their ownership structures and therefore may have less ability to raise significant additional capital, if required.

"Another key factor relevant when determining the financial impact of potential business interruption exposures for insurers is with regard to their ability to make recoveries from reinsurance programmes," said Myles Gould, director, analytics, AM Best. "Loss triggers may be a source of dispute with reinsurers, such as in the event of non-alignment of policy exclusions in primary wordings and reinsurance contracts."

"As the commentary notes, this test case outcome remains only one piece of a much larger puzzle, with a number of other business interruption contract triggers yet to be evaluated ahead of understanding the full liability for insurers," said Alex Rafferty, associate director, analytics, AM Best. "Additionally, this test case decision could be appealed."

AM Best will continue to review recent and future developments in respect of business interruption exposure for Australian insurers and assess the impact on the earnings, reserves and capital positions of rated entities.

To access a complimentary copy of this commentary, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=303416.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in New York, London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2020 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.


These press releases may also interest you

at 12:50
Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 11, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired QuidelOrtho Corporation ("QuidelOrtho"...

at 11:40
The "Global Needle Coke Market: Focus on Application, Type, Grade, End Use, and Country-Level Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global needle coke market was valued at $3.05...

at 11:15
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....

at 11:15
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...

at 09:35
Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research...

at 09:25
The "The U.S. Telehealth Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering The report includes in-depth analyses of: the scope of telehealth usage in the U.S., telehealth user demographics, pros and...



News published on and distributed by: